That wouldn't be harmed by an interim alpha spend. Nobody cares in this P2a if the alpha isn't perfectly holding to strict biostatistical rules. They could have done an interim and shown that as p=0.05, called it stat sig, and nobody (not even the FDA) would have squawked.
I just don't get it.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.